Biorestorative Therapies (NASDAQ:BRTX) Announces Quarterly Earnings Results, Hits Expectations

Biorestorative Therapies (NASDAQ:BRTX) announced its quarterly earnings results on Wednesday. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38), Zacks reports. Biorestorative Therapies had a negative net margin of 1,772.40% and a negative return on equity of 137.00%.

Biorestorative Therapies Trading Down 2.1%

NASDAQ:BRTX opened at $1.38 on Thursday. Biorestorative Therapies has a 12 month low of $1.19 and a 12 month high of $2.55. The stock has a market capitalization of $11.01 million, a price-to-earnings ratio of -1.09 and a beta of -0.29. The firm has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $1.61.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Biorestorative Therapies in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biorestorative Therapies has an average rating of “Sell”.

Biorestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.